Targeting the NF-κB pathway in neutrophils presents a potential strategy for cancer therapy, as it could reduce tumor-promoting inflammation and immune suppression while possibly enhancing anti-tumor immunity. The gene discussed is NFKB1; the disease is neoplasm.